Drugs / BEMFIVASTATIN
BEMFIVASTATIN
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01279590 | Mar → Nov 2011 | hyperlipidemia | Furiex Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEMFIVASTATIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314505 ↗ |
| Known as | Bemfivastatina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314505 ↗ |
| Known as | Bemfivastatine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314505 ↗ |
| Known as | PPD10558 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01279590 ↗ |
| Known as | RBX-10558 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314505 ↗ |
| Modality | Small molecule | — CHEMBL5314505 ↗ |
| Route | Oral | “40 mg orally twice daily for 4 weeks and 80 mg orally twice daily for 8 weeks” NCT01279590 ↗ |